Stephen Strittmatter

Director at Allyx Therapeutics.

New Haven, CT
Allyx Therapeutics

Raised on Allyx Therapeutics filings

$29.8M

of $34M offered across 2 Form D filings

Form D filings: 2
Teammates: 7
Last filing: May 11, 2026

Company

Allyx Therapeutics

Biotech · New Haven, CT

Oral drug to protect synapses in Alzheimer's

Oral drug to protect synapses in Alzheimer's

Investors: 12
Still open: $4.2M

Investors: 12
Sector: Biotech
HQ: New Haven, CT

Allyx Therapeutics filings

Allyx Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
May 11, 2026	Equity	$26.4M/ $30M	Form D
Mar 3, 2026	Option to acquire	$3.3M/ $4M	Form D

EquityFiled May 11, 2026Form D
$26.4M/ $30M
Option to acquireFiled Mar 3, 2026Form D
$3.3M/ $4M

Works with

Also named on Allyx Therapeutics filings

Dr. Stephen BlochChief Executive Officer, Form D signerForm D signer Kevin RakinDirector Jennifer GablerExecutive Officer Gregory P HoDirector Robert A BettigoleDirector Paul FonteyneDirector Timothy SiegertExecutive Officer